Combigan®
Brimonidine 0.2% / Timolol 0.5% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in glaucoma or ocular hypertension needing adjunctive or replacement therapy
1 drop in the affected eye(s) BID, approximately 12 hours apart
IOP falls 4.4 to 7.6 mmHg, more than timolol at every timepoint but not brimonidine at 5 PM.
Replacement therapy for inadequately controlled IOP in glaucoma or ocular hypertension
one drop in the affected eye(s) twice daily approximately 12 hours apart; IOP-lowering slightly less than concomitant timolol 0.5% twice a day plus brimonidine 0.2% three times per day
Contraindications
- Reactive airway disease including bronchial asthma
- A history of bronchial asthma
- Severe chronic obstructive pulmonary disease
- Sinus bradycardia
- Second or third degree atrioventricular block
- Overt cardiac failure
- Cardiogenic shock
- Neonates and infants (pediatric patients younger than 2 years old)
- Hypersensitivity to any component of this medication
0.2%/0.5% solution, 5 mL in 10 mL bottle, 10 mL in 10 mL bottle, 15 mL in 15 mL bottle
Fixed combination of brimonidine, a relatively selective alpha-2 adrenergic agonist that fluorophotometric studies suggest has a dual mechanism of reduced aqueous humor production and increased uveoscleral outflow, and timolol, a beta 1 and beta 2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Both components lower elevated IOP, with peak ocular hypotensive effect at about 2 hours for brimonidine and 1 to 2 hours for timolol.
Warnings & Precautions
- Severe respiratory or cardiac reactions: The timolol component can be absorbed systemically, so the adverse reactions of systemic beta-blockers may occur; death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure have been reported following systemic or ophthalmic timolol, and ophthalmic beta-blockers may impair compensatory tachycardia and increase risk of hypotension.
- Cardiac failure: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure; discontinue at the first sign or symptom.
- Obstructive pulmonary disease: Patients with mild or moderate COPD, bronchospastic disease, or a history of bronchospastic disease should, in general, not receive beta-blocking agents; bronchial asthma, a history of asthma, and severe COPD are outright contraindications.
- Potentiation of vascular insufficiency: COMBIGAN may potentiate syndromes associated with vascular insufficiency; use with caution in depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
- Increased allergen reactivity: Patients with atopy or prior severe anaphylaxis may be more reactive on repeat challenge and unresponsive to usual epinephrine doses.
- Muscle weakness: Beta-blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness), and timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
- Masked hypoglycemia: Beta-blockade may mask the signs and symptoms of acute hypoglycemia; use with caution in patients subject to spontaneous hypoglycemia and in diabetic patients (especially those with labile diabetes) receiving insulin or oral hypoglycemic agents.
- Masked thyrotoxicosis: Beta-blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism; manage patients suspected of developing thyrotoxicosis carefully to avoid abrupt withdrawal, which might precipitate a thyroid storm.
- Ocular hypersensitivity: Reported with brimonidine 0.2% solutions, with some reported to be associated with an increase in IOP.
- Pediatric somnolence: In the supporting pediatric study of brimonidine 0.2% TID added to a beta-blocker, somnolence occurred in 50% to 83% of patients 2 to 6 years; in patients 7 years of age or older (>20 kg), somnolence appears to occur less frequently (25%). Approximately 16% of patients discontinued from the study due to somnolence.
- Impairment of reflexes during surgery: Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli, which may augment the risk of general anesthesia. Some patients have experienced protracted severe hypotension during anesthesia, and difficulty in restarting and maintaining the heartbeat has also been reported.
- Additive beta-blockade: Patients receiving an oral or intravenous beta-blocker with COMBIGAN should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.
- Atrioventricular conduction disturbances and hypotension: Use caution with oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension; in patients with impaired cardiac function, avoid co-administration. Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.
- Additive or potentiating effect: The possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
- Increased hypotension: MAO inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension; caution is advised.
- Bacterial keratitis: Reported with contaminated multiple-dose containers, in most cases in eyes with concurrent corneal disease or a disruption of the ocular epithelial surface. Do not touch the tip of the dispensing container to the eye or surrounding structures; serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
- Soft contact lenses: Benzalkonium chloride may be absorbed by soft lenses; remove before instillation and reinsert after 15 minutes.
Common Side Effects
The most common adverse reactions (approximately 5% to 15%) were allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging. Asthenia, blepharitis, corneal erosion, depression, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, eyelid pruritus, foreign body sensation, headache, hypertension, oral dryness, somnolence, superficial punctate keratitis, and visual disturbance occurred in 1% to 5%. Postmarketing reactions include bradycardia, eyelid erythema extending to the cheek or forehead, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, rash, and vasodilation), syncope, and tachycardia, and, in infants receiving brimonidine, apnea, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence.
Pregnancy: No adequate and well-controlled studies in pregnant women, and postmarketing and published data are insufficient to establish a drug-associated risk. Oral brimonidine during organogenesis produced no adverse developmental effects at 580 times (rats) and 37 times (rabbits) the recommended human ophthalmic dose, and oral timolol showed no fetal malformations up to 4,200 times.
Lactation: Not recommended during lactation because of the potential for CNS depression and apnea in the breastfed infant. Timolol is detected in human milk; brimonidine excretion in human milk is unknown but occurs in rat milk.
Contraindicated under 2 years; safety and effectiveness established from age 2 and older.